GlassScriptPhysician profile
Vrinda S Bhasin
NPI 1740660133
$2,831.24
in general payments reported to CMS, 2019-2025
23 companies · $2,276 in 2025
The $2,276 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $220 · 2023: $154 · 2024: $182 · 2025: $2,276.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,325 · Food and Beverage: $1,286.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,324.93 |
| Food and Beverage | $1,286.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,860.86 | 2025 | Synchromedii |
| Merck Sharp & Dohme LLC | $122.19 | 2022-2025 | Keytruda, Welireg, Lynparza |
| Puma Biotechnology, INC. | $101.51 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $98.79 | 2022-2024 | Enhertu, Imfinzi |
| Pharmaessentia USA Corporation | $97.54 | 2024-2025 | Besremi |
| Incyte Corporation | $70.22 | 2022-2025 | Jakafi |
| Novartis Pharmaceuticals Corporation | $63.43 | 2023-2024 | |
| Blueprint Medicines Corporation | $50.97 | 2022-2025 | Ayvakit |
| Abbvie INC. | $33.16 | 2025 | |
| Averitas Pharma INC. | $28.56 | 2025 | Qutenza |
| Pfizer INC. | $28.36 | 2025 | |
| Adc Therapeutics America, INC. | $27.69 | 2025 | |
| Eisai INC. | $27.64 | 2023 | |
| Tersera Therapeutics LLC | $27.54 | 2024 | Quzyttir |
| Janssen Biotech, INC. | $26.10 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Servier Pharmaceuticals LLC | $24.46 | 2022 | |
| Taiho Oncology, INC. | $23.97 | 2025 | |
| Aveo Pharmaceuticals, INC. | $23.15 | 2022 | |
| Karyopharm Therapeutics INC. | $22.74 | 2023 | Xpovio |
| Apellis Pharmaceuticals, INC. | $20.08 | 2025 | Empaveli |
| E.R. Squibb & Sons, L.L.C. | $18.72 | 2022 | |
| Geron Corporation | $17.65 | 2025 | Rytelo |
| Amgen INC. | $15.91 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vrinda Bhasin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.